Revolution Medicines awarded FDA voucher tied to daraxonrasib

Rhea-AI Filing Summary

Revolution Medicines (RVMD) announced an FDA milestone. On October 16, 2025, the U.S. Food and Drug Administration granted the company a non‑transferrable voucher for daraxonrasib, its RAS(ON) multi‑selective inhibitor, under the Commissioner’s National Priority Voucher pilot program.

This update signals regulatory recognition tied to daraxonrasib’s program status. The voucher is non‑transferrable and is associated specifically with the FDA’s pilot initiative. No financial terms or commercial arrangements were disclosed in this notice.

Insights

Biopharma regulatory analyst

FDA granted RVMD a non‑transferrable voucher for daraxonrasib.

Revolution Medicines reported that the FDA granted a non‑transferrable voucher for daraxonrasib on October 16, 2025 under the Commissioner’s National Priority Voucher pilot program. The filing links the voucher specifically to the company’s RAS(ON) multi‑selective inhibitor.

The announcement indicates a defined FDA action tied to a pilot program. The filing does not outline mechanics, tradability beyond "non‑transferrable," or financial implications. Any operational impact would depend on program details not included here.

Subsequent disclosures may clarify how the voucher interacts with daraxonrasib’s development path or regulatory timelines, if applicable.

false 0001628171 0001628171 2025-10-16 2025-10-16 0001628171 rvmdw:CommonStock0.0001ParValuePerShareMember 2025-10-16 2025-10-16 0001628171 rvmdw:WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member 2025-10-16 2025-10-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 16, 2025

REVOLUTION MEDICINES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39219		47-2029180
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

700 Saginaw Drive
Redwood City, California		94063
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 481-6801

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		RVMD		The Nasdaq Stock Market LLC
Warrants to purchase 0.1112 shares of common stock expiring 2026		RVMDW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 16, 2025, Revolution Medicines, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has granted the Company a non-transferrable voucher for daraxonrasib, the Company’s RAS(ON) multi-selective inhibitor, under the Commissioner’s National Priority Voucher pilot program.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				REVOLUTION MEDICINES, INC.
Date: October 16, 2025				By:		/s/ Mark A. Goldsmith
						Mark A. Goldsmith, M.D., Ph.D.
						President and Chief Executive Officer

FAQ

What did RVMD announce on October 16, 2025?

RVMD announced the FDA granted a non‑transferrable voucher for daraxonrasib under the Commissioner’s National Priority Voucher pilot program.

Which RVMD program is associated with the FDA voucher?

The voucher is associated with daraxonrasib, RVMD’s RAS(ON) multi‑selective inhibitor.

Is the FDA voucher transferrable?

No. The company states the voucher is non‑transferrable.

What FDA initiative is referenced in RVMD’s update?

The Commissioner’s National Priority Voucher pilot program.

Did RVMD disclose financial terms related to the voucher?

No financial terms or commercial details are included in the announcement.